Trial Profile
Evaluation of efficacy and safety after treatment of twice daily NovoMix30 in patients with type 2 diabetes A multi-centre, open-labelled, single-arm tria (Phase 4)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Apr 2012 New trial record